Summit Therapeutics (SUMM) Hits New 52-Week Low at $23.04

Shares of Summit Therapeutics PLC (LON:SUMM) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as GBX 23.04 ($0.30) and last traded at GBX 24 ($0.31), with a volume of 24511 shares trading hands. The stock had previously closed at GBX 24 ($0.31).

In related news, insider Leopoldo Zambeletti sold 11,358 shares of the business’s stock in a transaction dated Wednesday, October 24th. The stock was sold at an average price of GBX 28 ($0.37), for a total transaction of £3,180.24 ($4,155.55).

COPYRIGHT VIOLATION WARNING: This report was first reported by WKRB News and is owned by of WKRB News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at

Summit Therapeutics Company Profile (LON:SUMM)

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

See Also: Float

Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply